New strategic central laboratory facility investment, with 2026 capex expected at about 4% of revenue to support long-term Central Labs growth.
Marker by Labcorp genetic health panel is planned for launch in August 2026 through Labcorp OnDemand, adding a consumer genetics offering.
Medicare coverage for Labcorp's NASHnext blood-based liver disease test begins in mid-August 2026, expanding patient access to MASH detection.
Labcorp was awarded a Department of Defense contract to provide laboratory testing for service members and families across military hospitals worldwide.
Diagnostics segment FY2026 revenue guidance midpoint was raised by about 20 basis points, reflecting confidence in specialty testing, reference testing, and deal delivery.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Labcorp Holdings Inc. and 4,900+ companies.